Investigating new technologies to optimise your freeze-drying processes, improve homogeneity, stability and scale-up

Over 60% of biologicals currently on the market are lyophilized, and that statistic is only rising. Clearly, lyophilization is a process vital to increasing the shelf life and stability of biologicals while decreasing transport costs.

But you already know that. Like most of your peers, you’re probably familiar with both the benefits and drawbacks of lyophilization. You don’t need to be told how important lyophilization is – you just need help optimising your processes.

That’s why Pharma IQ has organised the 2nd Annual Lyophilization for Biologicals, conference which will take place 24th-25th January 2012 in Munich, Germany.

Following on the success of our inaugural Lyophilization for Biologics conference this past January, we have designed the second event to bring together like-minded professionals working in formulation, process engineering and development, R&D and manufacturing to provide an opportunity to discuss and share experiences and innovations through presentations, panel discussions and roundtables.

Key topics for 2012 will include:

• Improving the homogeneity of your lyophilized materials
• Successfully scaling up the manufacture of lyophilized biologicals
• Utilizing TDLAS to control your freeze drying processes
• Using QbD procedures to greatly enhance your lyophilisation cycle
• Applying risk management and PAT tools to optimise your lyophilisation development and validation

…And don’t miss the pre-conference Focus Day on alternate delivery methods (like dual-chamber syringes and needle-free injections) and their applicability to your facility!

Sponsors	Media Partners